中国普外基础与临床杂志

中国普外基础与临床杂志

GnRHa 对年轻乳腺癌化疗患者卵巢功能的保护作用

查看全文

目的 总结促性腺激素释放激素激动剂(GnRHa)对年轻乳腺癌卵巢功能保护的研究进展,旨在对临床工作提供参考。 方法 通过计算机检索 PubMed、中国知网、万方等数据库,收集近 5 年来关于 GnRHa 对年轻乳腺癌化疗患者卵巢功能的保护作用的相关文献,进行综述。 结果 年轻乳腺癌患者面临长期生存、生活质量、社会心理压力等方面的问题,化疗可对卵巢功能造成不可逆的损害,而化疗联合 GnRHa 有助于预防卵巢早衰,从而提高化疗患者的生活质量。 结论 化疗联合 GnRHa 利于年轻乳腺癌卵巢功能的保护,减少卵巢早衰的发生,保留生育功能,无严重不良反应,且不影响化疗本身的疗效,但尚需更多的随机对照临床研究来证实。

Objective To summarize the progress of effect of gonadotropin-releasing hormone agonist on protecting ovarian function of young breast cancer patients, and to provide reference for clinical work. Methods Through searching of PubMed, CNKI, WanFang database, and other databases, We mainly collected relevant literatures in nearly five years, which concerning the gonadotropin-releasing hormone agonist to protect the ovarian function of young breast cancer patients who underwent chemotherapy. Results Young breast cancer patients were faced with problems about long-term survival, quality of life, social psychological pressure, and other related problems. Chemotherapy caused irreversible damage to the ovarian function. Chemotherapy combind with gonadotropin-releasing hormone agonist could prevent premature ovarian failure and improve their quality of life. Conclusion Gonadotropin-releasing hormone agonist combins with chemotherapy could protect the ovarian function for young breast cancer patients, and reduce ovarian premature failure and retain reproductive function with no serious adverse effect, in addition, it shall not affect the curative effect of chemotherapy itself, but still needs further randomized controlled clinical research.

关键词: 乳腺癌; 促性腺激素释放激素激动剂; 年龄; 卵巢功能

Key words: breast cancer; gonadotropin-releasing hormone agonist; age; ovarian function

登录后 ,请手动点击刷新查看全文内容。 没有账号,
1. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
2. Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol, 2014, 15(7): e279-e289.
3. Kreuser ED, Hetzel WD, Billia DO, et al. Gonadal toxicity following cancer therapy in adults: significance, diagnosis, prevention and treatment. Cancer Treat Rev, 1990, 17(2/3): 169-175.
4. Torino F, Barnabei A, De Vecchis L, et al. Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer. Crit Rev Oncol Hematol, 2014, 89(1): 27-42.
5. Axelrod D, Smith J, Kornreich D, et al. Breast cancer in young women. J Am Coll Surg, 2008, 206(6): 1193-1203.
6. Fredholm H, Eaker S, Frisell J, et al. Breast cancer in young women: poor survival despite intensive treatment. PLoS One, 2009, 4(11): e7695.
7. Sivasubramaniam PG, Zhang BL, Zhang Q, et al. Breast cancer disparities: a multicenter comparison of tumor diagnosis, characteristics, and surgical treatment in China and the U.S. Oncologist, 2015, 20(9): 1044-1050.
8. Yoon TI, Hwang UK, Kim ET, et al. Survival improvement in hormone-responsive young breast cancer patients with endocrine therapy. Breast Cancer Res Treat, 2017, 165(2): 311-320.
9. Anders CK, Hsu DS, Broadwater G, et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol, 2008, 26(20): 3324-3330.
10. Collins LC, Marotti JD, Gelber S, et al. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat, 2012, 131(3): 1061-1066.
11. Azim HA Jr, Partridge AH. Biology of breast cancer in young women. Breast Cancer Res, 2014, 16(4): 427.
12. Aalders KC, Postma EL, Strobbe LJ, et al. Contemporary locoregional recurrence rates in young patients with early-stage breast cancer. J Clin Oncol, 2016, 34(18): 2107-2114.
13. Tang LC, Yin WJ, Di GH, et al. Unfavourable clinicopathologic features and low response rate to systemic adjuvant therapy: results with regard to poor survival in young Chinese breast cancer patients. Breast Cancer Res Treat, 2010, 122(1): 95-104.
14. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG); Clarke M, Coates AS, et al. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet, 2008, 371(9606): 29-40.
15. Tiong V, Rozita AM, Taib NA, et al. Incidence of chemotherapy-induced ovarian failure in premenopausal women undergoing chemotherapy for breast cancer. World J Surg, 2014, 38(9): 2288-2296.
16. Ganz PA, Land SR, Geyer CE Jr, et al. Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol, 2011, 29(9): 1110-1116.
17. Sukumvanich P, Case LD, Van Zee K, et al. Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: a prospective study. Cancer, 2010, 116(13): 3102-3111.
18. Oktem O, Oktay K. A novel ovarian xenografting model to characterize the impact of chemotherapy agents on human primordial follicle reserve. Cancer Res, 2007, 67(21): 10159-10162.
19. Goldhirsch A, Gelber RD, Castiglione M. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group. Ann Oncol, 1990, 1(3): 183-188.
20. Tham YL, Sexton K, Weiss H, et al. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol, 2007, 30(2): 126-132.
21. Koga C, Akiyoshi S, Ishida M, et al. Chemotherapy-induced amenorrhea and the resumption of menstruation in premenopausal women with hormone receptor-positive early breast cancer. Breast Cancer, 2017, 24(5): 714-719.
22. Vriens IJ, De Bie AJ, Aarts MJ, et al. The correlation of age with chemotherapy-induced ovarian function failure in breast cancer patients. Oncotarget, 2017, 8(7): 11372-11379.
23. Petrek JA, Naughton MJ, Case LD, et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol, 2006, 24(7): 1045-1051.
24. Ben-Aharon I, Meizner I, Granot T, et al. Chemotherapy-induced ovarian failure as a prototype for acute vascular toxicity. Oncologist, 2012, 17(11): 1386-1393.
25. Jeon SJ, Lee JI, Jeon MJ, et al. Prognostic effects of adjuvant chemotherapy-induced amenorrhea and subsequent resumption of menstruation for premenopausal breast cancer patients. Medicine (Baltimore), 2016, 95(14): e3301.
26. Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist, 2007, 12(9): 1044-1054.
27. Ataya KM, McKanna JA, Weintraub AM, et al. A luteinizing hormone-releasing hormone agonist for the prevention of chemotherapy-induced ovarian follicular loss in rats. Cancer Res, 1985, 45(8): 3651-3656.
28. Wang Y, Tian X, Liang L, et al. Mechanistic study on triptorelin action in protecting from 5-FU-induced ovarian damage in rats. Oncol Res, 2014, 22(5/6): 283-292.
29. Parlakgumus HA, Kilicdag EB, Bolat FA, et al. GNRH agonists and antagonists in rescue for cyclophosphamide-induced ovarian damage: friend or foe? Arch Gynecol Obstet, 2015, 291(6): 1403-1410.
30. Blumenfeld Z, Avivi I, Ritter M, et al. Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women. J Soc Gynecol Investig, 1999, 6(5): 229-239.
31. Blumenfeld Z, Shapiro D, Shteinberg M, et al. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus, 2000, 9(6): 401-405.
32. Del Mastro L, Boni L, Michelotti A, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA, 2011, 306(3): 269-276.
33. Lambertini M, Boni L, Michelotti A, et al. Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial. JAMA, 2015, 314(24): 2632-2640.
34. Moore HC, Unger JM, Phillips KA, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med, 2015, 372(10): 923-932.
35. Munhoz RR, Pereira AA, Sasse AD, et al. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: a systematic review and meta-analysis. JAMA Oncol, 2016, 2(1): 65-73.
36. Wong M, O’Neill S, Walsh G, et al. Goserelin with chemotherapy to preserve ovarian function in pre-menopausal women with early breast cancer: menstruation and pregnancy outcomes. Ann Oncol, 2013, 24(1): 133-138.
37. Bai F, Lu Y, Wu K, et al. Protecting effects of gonadotropin-releasing hormone agonist on chemotherapy-induced ovarian damage in premenopausal breast cancer patients: a systematic review and meta-analysis. Breast Care (Basel), 2017, 12(1): 48-52.
38. Demeestere I, Brice P, Peccatori FA, et al. No evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: final long-term report of a prospective randomized trial. J Clin Oncol, 2016, 34(22): 2568-2574.
39. Gerber B, von Minckwitz G, Stehle H, et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol, 2011, 29(17): 2334-2341.
40. Munster PN, Moore AP, Ismail-Khan R, et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol, 2012, 30(5): 533-538.
41. Elgindy EA, El-Haieg DO, Khorshid OM, et al. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. Obstet Gynecol, 2013, 121(1): 78-86.
42. National Comprehensive Cancer Network. https://www.nccn.org/.